Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

A prospective, non-randomized, multicentre, open, dose-finding study of a c arboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO s tage Ic-IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.), 139 eligible patients (Pts) (median age 56 years, range 28-85) were given a tot al of 750 cycles of chemotherapy in 5 cohorts: Co1, 32 pts, 169 cycles (C a t AUC 5 + D 60 mg/m(2)); Co2, 22 pts, 122 cycles (5 + 75), Co3, 29 pts, 156 cycles (6 + 75), Co4, 27 pts, 146 cycles (7 + 75), Co5, 30 pts, 157 cycles (6 + 85). 110 patients (79%) completed 6 cycles; 17 (12%) stopped due to t oxicity. 104 patients (75%) had CTC grade IV neutropenia, and 5 patients (4 %) had this associated with fever. There were 2 probable treatment-related deaths. Only 8 patients (6%) experienced grade II-III neurotoxicity (all se nsory: no motor > grade I). The maximum tolerated dose was reached in cohor ts 4 and 5, and the dose limiting toxicities were myelosuppression and diar rhoea. The overall response rate for the study was 66% (49/74); CA125 respo nse was 75% (70/93). Median progression-free survival was 16.6 months (95% CI 13.3-19.1). Recommended doses are carboplatin AUC 5 (via Cr-51 EDTA) or AUC 6 (if calculated) plus docetaxel 75 mg/m(2). A randomized trial compari ng this regimen with carboplatin-paclitaxel has just completed recruitment. (C) 2001 Cancer Research Campaign.